Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
colostrinin
- Development stage
- Unknown
- Lead developer
- ReGen Therapeutics
- Modality
- Peptides
- Administration
- Oral
01
Overview
Colostrinin is a proline-rich polypeptide (PRP) complex derived from ovine (sheep) colostrum. It functions as an immunomodulator and a cytokine-like factor, notably inducing the production of interferon-gamma (IFN-gamma) and other cytokines in human leukocyte cultures. In the context of neurodegenerative diseases, colostrinin has been investigated for its potential to inhibit the aggregation of amyloid-beta and dissolve existing fibrils, which are pathological hallmarks of Alzheimer's disease. Clinical studies have suggested that oral administration of colostrinin may stabilize or improve cognitive function in patients with mild to moderate Alzheimer's dementia. The drug was primarily developed by ReGen Therapeutics and has demonstrated a favorable safety profile with only mild, transient side effects such as insomnia and tiredness.
- Brand names
- Cognatein
- Other names
- Proline-rich polypeptide complexProline-rich polypeptide
02
Targets
IFNG (Interferon gamma)Amyloid-beta aggregate (N-terminal epitope)
Beyond the preview
Go deeper on colostrinin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on colostrinin.